Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine
Discover Servier
Servier Joins Everest Climb to Fight Cancer Benefitting Fred Hutchinson Cancer Research Center
Servier Submits a Marketing Authorization Application to the European Medicines Agency (EMA) for TIBSOVO® (ivosidenib tablets) for Patients with IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
Three Tips to Help Patients & Their Families Prepare for Survivorship
Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline
Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
New Data at ASH 2021 Reinforces the Strength of Servier’s Hematology Portfolio
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma